NeuroDerm has completed 8 Phase-I and clinical pharmacology studies, ranging from small dose-finding studies to 12-month population pharmacokinetics studies. These studies support the conclusions that ND0612 provides stable and continuous delivery of levodopa and carbidopa at clinically meaningful levels.